Based on HTRF technology, the kit contains all the reagents needed to quantify cAMP, ensuring that you benefit from a complete tool for your needs.

Revvity's HTRF cAMP kits are best suited for measuring cAMP modulations in response to Gs-activation, leveraging an optimized combination of robustness and sensitivity

At Revvity, we regard "impossibility" as inspiration and "inability" as the driving force. Revvity offers health science solutions, cutting - edge technologies and professional services, with its business covering the entire end - to - end process of scientific research exploration, development, diagnosis, and treatment. Relying on years of in - depth cultivation in fields such as translational multi - omics technology, biomarker identification, imaging, disease prediction, screening, detection and diagnosis, and informatics, Revvity is using the power of technology to break through the boundaries of human potential.

In 2023, Revvity's turnover exceeded $2.7 billion. It has more than 11,000 employees worldwide and provides diverse services for customers such as pharmaceutical and biotechnology enterprises, diagnostic laboratories, scientific research institutions and government agencies. The company is a member of the S&P 500 Index, and its customers are spread across more than 190 countries and regions around the world.